Drug Profile
Midazolam intranasal spray - MEDIR
Alternative Names: Nasal spray midazolam - MEDIRLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator MEDIR
- Class Antiepileptic drugs; Benzodiazepines; Chlorinated hydrocarbons; Fluorobenzenes; Hypnosedatives; Imidazoles; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Epilepsy; Sedation
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for clinical-Phase-Unknown development in Epilepsy in Netherlands (Intranasal, Spray)
- 28 Oct 2018 No recent reports of development identified for clinical-Phase-Unknown development in Sedation in Netherlands (Intranasal, Spray)
- 24 Sep 2015 Midazolam intranasal spray is available for commercialisation (MEDIR website, September 2015)